Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retrospective Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms

NCT02842229 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02842229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02842229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retrospective Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms
Lead sponsor
Celgene
Phase
Observational
Overall status
Completed
Start date
July 20, 2016
Completion date
February 2, 2017
Enrollment
117 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia myeloid acute, leukemia, lymphocytic, chronic, b-cell, multiple myeloma, myelodysplastic syndromes